Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit 'ALL'

Sattva S. Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Frederick L. Locke; Yi Lin; Nitin Jain; Naval Daver; Alison M. Gulbis; Sherry Adkins; Katayoun Rezvani; Patrick Hwu; Elizabeth J. Shpall

doi:10.1038/nrclinonc.2018.20

Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit 'ALL'

Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Frederick L. Locke, Yi Lin, Nitin Jain, Naval Daver, Alison M. Gulbis, Sherry Adkins, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall

Hematology

Research output: Contribution to journal › Letter › peer-review

43 Scopus citations

Original language	English (US)
Pages (from-to)	218
Number of pages	1
Journal	Nature Reviews Clinical Oncology
Volume	15
Issue number	4
DOIs	https://doi.org/10.1038/nrclinonc.2018.20
State	Published - Apr 1 2018

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/nrclinonc.2018.20

Cite this

@article{d4cc7fe73aa14cd5b54d0570afa5258b,

title = "Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit 'ALL'",

author = "Neelapu, {Sattva S.} and Sudhakar Tummala and Partow Kebriaei and William Wierda and Locke, {Frederick L.} and Yi Lin and Nitin Jain and Naval Daver and Gulbis, {Alison M.} and Sherry Adkins and Katayoun Rezvani and Patrick Hwu and Shpall, {Elizabeth J.}",

note = "Funding Information: S.S.N. has received research support from Bristol‑Myers Squibb, Celgene, Cellectis, Kite Pharma, Merck, and Poseida Therapeutics. S.S.N. has also served as a consult‑ ant and/or Scientific Advisory Board member for Celgene, Kite Pharma, Merck, and Novartis. S.T. served as a Scientific Advisory Board member for Kite Pharma. F.L.L. has served as a Scientific Advisory Board member for Kite Pharma, and as a Consultant to Cellular Biomedicine Group. Y.L. has received research funding from Janssen. N.J. has received research support from Abbvie, ADC Therapeutics, Bristol‑Myers Squibb, Celgene, Genentech, Incyte, Pharmacyclics, Pfizer, Seattle Genetics, Servier, and Verastem. N.J. has also served on the advisory board and received honorarium from Adaptive Biotechnologies, ADC Therapeutics, Novartis, Novimmune, Pharmacyclics, Pfizer, Servier, and Verastem. N.D. has received research support from Bristol‑Myers Squibb, Daichi‑Sanky, Incyte, Karyopharm, Pfizer, and Sunesis. N.D. has also received served as a consultant for Incyte, Jazz, Karyopharm, Novartis, Otsuka, Pfizer, and Sunesis. K.R. is on the Independent Data Monitoring Committee for Kiadis Pharma. The other authors declare no competing interests.",

year = "2018",

month = apr,

day = "1",

doi = "10.1038/nrclinonc.2018.20",

language = "English (US)",

volume = "15",

pages = "218",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Toxicity management after chimeric antigen receptor T cell therapy

T2 - One size does not fit 'ALL'

AU - Neelapu, Sattva S.

AU - Tummala, Sudhakar

AU - Kebriaei, Partow

AU - Wierda, William

AU - Locke, Frederick L.

AU - Lin, Yi

AU - Jain, Nitin

AU - Daver, Naval

AU - Gulbis, Alison M.

AU - Adkins, Sherry

AU - Rezvani, Katayoun

AU - Hwu, Patrick

AU - Shpall, Elizabeth J.

N1 - Funding Information: S.S.N. has received research support from Bristol‑Myers Squibb, Celgene, Cellectis, Kite Pharma, Merck, and Poseida Therapeutics. S.S.N. has also served as a consult‑ ant and/or Scientific Advisory Board member for Celgene, Kite Pharma, Merck, and Novartis. S.T. served as a Scientific Advisory Board member for Kite Pharma. F.L.L. has served as a Scientific Advisory Board member for Kite Pharma, and as a Consultant to Cellular Biomedicine Group. Y.L. has received research funding from Janssen. N.J. has received research support from Abbvie, ADC Therapeutics, Bristol‑Myers Squibb, Celgene, Genentech, Incyte, Pharmacyclics, Pfizer, Seattle Genetics, Servier, and Verastem. N.J. has also served on the advisory board and received honorarium from Adaptive Biotechnologies, ADC Therapeutics, Novartis, Novimmune, Pharmacyclics, Pfizer, Servier, and Verastem. N.D. has received research support from Bristol‑Myers Squibb, Daichi‑Sanky, Incyte, Karyopharm, Pfizer, and Sunesis. N.D. has also received served as a consultant for Incyte, Jazz, Karyopharm, Novartis, Otsuka, Pfizer, and Sunesis. K.R. is on the Independent Data Monitoring Committee for Kiadis Pharma. The other authors declare no competing interests.

PY - 2018/4/1

Y1 - 2018/4/1

UR - http://www.scopus.com/inward/record.url?scp=85044213195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044213195&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2018.20

DO - 10.1038/nrclinonc.2018.20

M3 - Letter

C2 - 29434334

AN - SCOPUS:85044213195

SN - 1759-4774

VL - 15

SP - 218

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 4

ER -

Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit 'ALL'

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this